1 week Ago By ABMN Staff
Orion Portfolio Solutions LLC trimmed its holdings in Immunocore Holdings plc ( NASDAQ:IMCR – Free Report ) by 37.1% in the 4th quarter, HoldingsChannel.com reports.
The fund owned 13,017 shares of the company’s stock after selling 7,675 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Immunocore were worth $384,000 as of its most recent SEC filing. Several other hedge funds also recently modified their holdings of the business.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Immunocore by 7,437.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company’s stock valued at $2,872,000 after acquiring an additional 91,033 shares during the last quarter.
Verition Fund Management LLC acquired a new stake in Immunocore in the 3rd quarter worth approximately $739,000. State Street Corp boosted its position in Immunocore by 63.9% during the third quarter.
State Street Corp now owns 76,671 shares of the company’s stock worth $2,387,000 after purchasing an additional 29,897 shares during the period. XTX Topco Ltd grew its holdings in Immunocore by 72.9% during the third quarter.
XTX Topco Ltd now owns 15,459 shares of the company’s stock valued at $481,000 after purchasing an additional 6,516 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of Immunocore by 25.
0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock valued at $17,007,000 after purchasing an additional 109,206 shares during the period.
Institutional investors and hedge funds own 84.50% of the company’s stock. Wall Street Analysts Forecast Growth Several research firms recently issued reports on IMCR.
Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 price objective on shares of Immunocore in a report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and set a $100.
00 price target on shares of Immunocore in a report on Wednesday, March 12th. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th.
Finally, Mizuho decreased their target price on Immunocore from $38.00 to $33.00 and set a “neutral” rating for the company in a research note on Monday.
One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $65.18.
Immunocore Stock Performance Shares of NASDAQ IMCR opened at $24.53 on Wednesday. Immunocore Holdings plc has a one year low of $24.
49 and a one year high of $62.74. The company has a current ratio of 3.
78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.
The business has a fifty day simple moving average of $29.39 and a 200 day simple moving average of $30.61.
The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -25.82 and a beta of 0.
75. Insider Activity In other Immunocore news, Director Bros. Advisors Lp Baker bought 807,338 shares of the firm’s stock in a transaction dated Monday, March 17th.
The shares were acquired at an average cost of $29.72 per share, for a total transaction of $23,994,085.36.
Following the transaction, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. The trade was a 60.
40 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website . Corporate insiders own 9.
10% of the company’s stock. Immunocore Profile ( Free Report ) Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.
It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. Further Reading Want to see what other hedge funds are holding IMCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunocore Holdings plc ( NASDAQ:IMCR – Free Report ).
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter ..
